**Clinical and epidemiological characteristics of Coronavirus Disease 2019
(COVID-19) patients**

Shing Cheng Tan

*UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur,
Malaysia*

Corresponding author:

Shing Cheng Tan, PhD

Address: UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

Email: sctan@ukm.edu.my

Tel: +6012-714 7142

Fax: +603-9171 7185

Summary

Background: Numerous groups have reported the clinical and epidemiological characteristics of Coronavirus Disease 2019 (COVID-19) cases; however, the data remained inconsistent. This paper aimed to pool the available data to provide a more complete picture of the characteristics of COVID-19 patients.

Methods: A systematic review and pooled analysis was performed. Eligible studies were identified from database and hand searches up to March 2, 2020. Data on clinical (including laboratory and radiological) and epidemiological (including demographic) characteristics of confirmed COVID-19 cases were extracted and combined by simple pooling.

Results: Of 644 studies identified, 69 studies (involving 48,926 patients) were included in the analysis. The average age of the patients was 49.16 years. A total of 51.46% of the patients were men and 52.32% were non-smokers. Hypertension (50.82%) and diabetes (20.89%) were the most frequent comorbidities observed. The most common symptoms were fever (83.21%), cough (61.74%), and myalgia or fatigue (30.22%). Altered levels of blood and biochemical parameters were observed in a proportion of the patients. Most of the patients (78.50%) had bilateral lung involvements, and 5.86% showed no CT findings indicative of viral pneumonia. Acute respiratory distress syndrome (28.36%), acute cardiac injury (7.89%) and acute kidney injury (7.60%) were the most common complications recorded.

Conclusions: Clinical and epidemiological characteristics of COVID-19 patients were mostly heterogeneous and non-specific. This is the most comprehensive report of the characteristics of COVID-19 patients to date. The information presented is important for improving our understanding of the spectrum and impact of this novel disease.

Introduction

There is an ongoing pandemic of viral pneumonia called Coronavirus Disease 2019 (COVID-19) which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. At the time of this writing, the disease has been reported to affect 634,835 people in more than 200 countries, territories or areas, and cause 29,891 deaths (1). Understanding the clinical and epidemiological characteristics of the disease is important for informing public health decision making, which would enable improvement of surveillance and effective planning of treatment. In January 2020, Huang et al. (2) published the first report on the characteristics of a series of COVID-19 patients in Wuhan, China, the first epicenter of the outbreak. Following that, many other groups have reported the clinical and epidemiological features of COVID-19 patients, both in China and in other parts of the world (3-12). However, most of these reports were limited by a small sample size, and the characteristics reported appeared to be inconsistent. For example, in a report involving 99 patients, Chen et al. (3) noted a much higher proportion of men than women, and suggested that men were generally more susceptible to SARS-CoV-2 infection. On the other hand, Shi et al. (4) found that the male-to-female ratio among the 81 patients included was close to 1:1, indicating that both genders were equally susceptible to COVID-19. Recently, the World Health Organization (WHO) has declared COVID-19 a global pandemic and the contagion shows no sign of slowing down (13). Thus, it is a timely prompt to obtain a more precise understanding of the disease by combining all available data in the literature. In this study, a systematic review and pooled analysis was performed to characterize the clinical and epidemiological features of COVID-19 patients.

Methods

Search strategy and selection criteria

Three separate searches were performed on PubMed database on March 2, 2020, using the keywords “COVID-19”, “2019-nCoV” and “SARS-CoV-2”. No language restriction was applied. After removal of duplicated records, screening by title and abstract was performed to identify potentially relevant studies. The full-texts of these potentially relevant studies were then evaluated. The reference lists of these studies were also hand-searched to identify additional records. Studies were included if they reported any clinical and/or epidemiological data of confirmed COVID-19 patients, regardless of their study design. However, review papers or studies employing secondary analysis of the previously available data were excluded from the analysis. In case of overlapping studies, the ones which the largest sample size or the most complete data set were included.

Data analysis

The following data were extracted from the included studies: name of first author, country, date of diagnosis, demographic data, smoking status, comorbidities, signs and symptoms, laboratory/biochemical data, CT findings, and complications of the disease. A simple pooling of data was performed to provide an overall summary of the clinical and epidemiological characteristics of the patients. All data are reported as absolute number and/or mean. As patient-level data were not available in majority of the studies, standard deviation could not be calculated.

Role of the funding source

There was no funding source for this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

The flowchart of study selection is depicted in Figure 1. A total of 644 records were identified from the PubMed searches. After deduplication, 517 unique records were identified. Following screening by title and abstract, 440 records were removed and full-texts of the remaining 77 studies were retrieved for assessment of eligibility. Five records were subsequently removed as they reported secondary data or contained insufficient data on clinical and/or epidemiological characteristics of the patients. In addition, three overlapping records were excluded. Eventually, 69 studies were included in the current analysis (2-12, 14-71). These 69 studies comprised a total of 48,926 confirmed COVID-19 patients, although only appropriate subcohorts were used in the analysis of each clinical/epidemiological characteristic. A great majority of these studies were from mainland China, while five were from Korea and one each from the USA, Germany, France, Australia, Italy, Singapore, Vietnam, Nepal, Hong Kong, and Taiwan.

The characteristics of the patients are shown in Table 1. The mean age of the patients was 49.16 years. The number of male patients was slightly higher than that of female (51.46% vs. 48.54%), and the number of non-smokers was slightly higher than that of smokers (52.32% vs. 47.68%). A minority (25.93%) of the patients had comorbidities, among which hypertension was the most common (50.82%), followed by diabetes (20.89%), cardiovascular and cerebrovascular diseases (16.54%), respiratory system disease (9.70%) and malignancy (2.05%). Most of the patients showed at least one sign or symptom at presentation, with only 0.8% of the patients were asymptomatic. The most common symptoms seen included fever (83.21%), cough (61.74%), myalgia or fatigue (30.22%), sputum production (20.22%), and dyspnea (16.97%). On average, the length from illness onset to dyspnea was 4.99 days.

The laboratory findings of the patients are also shown in Table 1. Majority (63.06%) of the patients had a normal leukocyte count, but as much as 24.14% and 12.80% respectively

showed decreased and increased leukocyte counts. Besides, 51.39% of the patients had a decreased lymphocyte count and 9.63% had a decreased platelet count. Increased levels of aspartate aminotransferase, creatinine, creatine kinase, lactate dehydrogenase, hypersensitive troponin I, procalcitonin and C-reactive protein were observed in 27.45%, 5.19%, 13.25%, 45.76%, 3.57%, 69.08% and 72.30% of the patients, respectively.

Analysis of computed tomography (CT) data revealed that most of the patients (78.50%) had bilateral lung involvements, while 15.65% had unilateral lung involvements and 5.86% showed no sign of viral pneumonia. In 41.18% of the patients, all five lung lobes were affected. On the other hand, as much as 17.03%, 11.46%, 12.69% and 17.65% patients respectively had one, two, three and four lobes affected.

It was unknown how many patients had complications following SARS-CoV-2 infection. Nonetheless, among the wide spectrum of complications observed, acute respiratory distress syndrome (ARDS) was most frequently documented (28.36%), followed by acute cardiac injury (7.89%) and acute kidney injury (7.60%).

Discussion

COVID-19 poses a significant burden on the healthcare system all over the world. A complete understanding of the characteristics of the disease is important for effective surveillance and public health response measures to be implemented in a timely manner. Currently, although we have some basic understanding of the clinical and epidemiological features of COVID-19 patients, our knowledge is insufficient. This is because inconsistencies still exist in the findings of many published reports, and the sample sizes in most of these reports were too small for a reliable summary to be made. In this work, a systematic review and pooled analysis was performed to combine data from 69 previous reports, in order to yield a more accurate summary of the clinical and epidemiological characteristics of COVID-19 patients.

In many instances, susceptibility to viral infections may be related to factors such as gender and smoking habits (72-74). For the former, it is believed that X chromosome inactivation in females may cause cellular mosaicism which ensures the presence of at least one functional copy of X-linked immune genes, thus conferring women an increased resistance against viral infections (75). In addition, estrogen, the major female sex hormone, is known to promote adaptive immune response (76), while testosterone, the primary sex hormone in men, could contribute to the suppression of the innate immune response, rendering men more susceptible to viral infections (77, 78). On the other hand, cigarette smoking may reduce the level of circulating immunoglobulins, immune cells, and pro-inflammatory cytokines, as well as disrupt the response of antibodies to antigens (72). For these reasons, some studies have suggested that men and smokers are more susceptible to SARS-CoV-2 infections (3, 79). In the present work, we noted that the ratios of male to female and smokers to non-smokers were close to 1:1. Although the relative risk or odds ratio of the association between these variables and SARS-CoV-2 infection could not be computed due to the lack of a comparison group, a proportion of approximately 1:1 suggests that susceptibility to SARS-CoV-2 infection is universal.

The present work also showed that the symptoms of COVID-19 were generally non-specific, thus the disease cannot be reliably distinguished from other infectious diseases based on the symptoms alone. The most commonly observed symptoms were similar to those of the previous coronavirus disease outbreaks (MERS and SARS), i.e. fever, cough, and myalgia or fatigue. Nevertheless, compared to MERS and SARS, the proportion of afebrile patients was much higher in COVID-19 (16.79% cf. 2% in MERS and 0-1% in SARS) (80). This indicates that a significant number of COVID-19 patients would be missed if surveillance and monitoring systems focus largely on temperature screening, as commonly practiced in airports (81, 82). The present work also showed that dyspnea was observed in only 16.97% of the patients. This contradicts with advisories and guidelines published by many health authorities, which suggest that dyspnea is a commonly observed symptom in COVID-19 (83-89). Besides, it was observed that 0.80% of the patients were asymptomatic. Currently, whether asymptomatic patients can transmit the virus to other individuals is not fully known, but it is highly possible (35). Thus, although the number of asymptomatic patients was low, identifying and isolating such patients to prevent uncontrolled disease spread would prove very challenging. It is therefore important for diagnostic tests to be performed on asymptomatic medium- and high-risk individuals to facilitate early detection and prevention of SARS-CoV-2 transmission. In addition to nucleic acid testing using real-time reverse transcription polymerase chain reaction, some studies have suggested the potential usability of chest CT for COVID-19 diagnosis (90, 91). However, in the present work, we found that 5.86% of the patients did not have abnormalities on CT scans. Thus, although CT findings have substantial accuracy in identifying the disease (90, 91), the results need to be interpreted with caution.

SARS-CoV-2 is known to infect a cell by first binding to its angiotensin converting enzyme 2 (ACE2) receptor (92). Apart from the lung, high expression of ACE2 receptor is also

observed in several other organs such as the heart, kidney, and intestine, as well as the in lymphocytes (93, 94). Several previous studies reported that a decreased lymphocyte count was a common feature of SARS-CoV-2 infection (2, 3, 7, 30, 41). In the present work, lymphopenia was observed in 51.39% of the patients. A decreased lymphocyte count implies a weakening adaptive immune system. Considering the high expression of ACE2 in lymphocytes, it has been postulated that SARS-CoV-2 may directly infect and attack lymphocytes, thus impairing the immune system (95). Besides the decrease in lymphocyte count, the present study also showed that many COVID-19 patients had increased levels of C-reactive protein, creatine kinase, lactate dehydrogenase and procalcitonin. High levels of C-reactive protein and creatine kinase suggest that sustained inflammatory response occurs following SARS-CoV-2 infection, whereas high levels of lactate dehydrogenase and procalcitonin indicate the virus could, either directly or indirectly, cause tissue injury. A previous work reported that a low lymphocyte count and high levels of lactate dehydrogenase and C-reactive protein were among the parameters found to be correlated with severity of lung injury in COVID-19 patients, as measured using the Murray scores (17). Nonetheless, the relationship between these variables and severity of COVID-19 was not investigated in the present work due to the insufficient data available.

A few limitations exist in the present work. First, there were instances where a same patient was described in multiple reports (15, 96). Efforts have been made to identify such patients by meticulously reviewing the descriptions of the patients in each report. However, since all patients were anonymized, it was challenging to identify all overlapping patients. Thus, there is a possibility that some overlapping patients were not removed from our analysis and their characteristics were overreported. Besides, since patient-level data were not reported in most of the studies, median values and standard deviations, which understandably provide more meaningful information, could not be computed. Finally, as mentioned above, various

comparisons among the patients (e.g. severe vs. mild, and death vs. survivor) could not be analyzed due to insufficient data available.

Conclusion

In conclusion, this report has successfully provided a more complete picture of the clinical and epidemiological characteristics of COVID-19 patients. A wide variation exists in the clinical manifestation of the disease. As the outbreak continues to escalate and SARS-CoV-2 continues to mutate (97), it is important to consistently update the characteristics of the patients in order to monitor whether evolving strains of the virus could cause the disease differently. Sharing of clinical and epidemiological data among the scientific community is highly important for informing public health decision making for controlling the spread of the disease.

219 **Contributor**

220 SCT contributed solely to this work.

221

222 **Declaration of interests**

223 The author declares no competing interests.

224

225 **Acknowledgments**

226 No funding was obtained for this work.

References

1. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report – 69. 2020.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* (London, England). 2020;395(10223):497-506.
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* (London, England). 2020;395(10223):507-13.
4. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *The Lancet Infectious diseases*. 2020.
5. Albarello F, Pianura E, Di Stefano F, Cristofaro M, Petrone A, Marchioni L, et al. 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020.
6. Ki M, nCo VT. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Republic of Korea. *Epidemiology and health*. 2020:e2020007.
7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Jama*. 2020.
8. Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. *Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin*. 2020;25(6).
9. COVID-19 National Incident Room Surveillance Team. COVID-19, Australia: Epidemiology Report 4 (Reporting week ending 19:00 AEDT 22 February 2020). *Communicable diseases intelligence* (2018). 2020;44.
10. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chinese medical journal*. 2020.
11. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. *The Journal of infection*. 2020.
12. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory medicine*. 2020.
13. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 2020. Available from: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>.
14. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. *Bioscience trends*. 2020.
15. Kim JY, Choe PG. The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures. 2020;35(5):e61.
16. Lim J, Jeon S. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. 2020;35(6):e79.

17. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Science China Life sciences*. 2020.
18. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *Radiology*. 2020.
19. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *The New England journal of medicine*. 2020;382(8):727-33.
20. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. *The New England journal of medicine*. 2020.
21. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. 2020.
22. Chinese National Health Commission. [Briefing on the pneumonia epidemic situation, 23 January 2020] 2020. Available from: <http://www.nhc.gov.cn/yjb/s3578/202001/5d19a4f6d3154b9fae328918ed2e3c8a.shtml>.
23. Chung M, Bernheim A. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). 2020:200230.
24. Lei J, Li J, Li X, Qi X. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia. 2020:200236.
25. Shi H, Han X. Evolution of CT Manifestations in a Patient Recovered from 2019 Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China. 2020:200269.
26. Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging Coronavirus 2019-nCoV Pneumonia. 2020:200274.
27. Fang Y, Zhang H. CT Manifestations of Two Cases of 2019 Novel Coronavirus (2019-nCoV) Pneumonia. 2020:200280.
28. Duan YN, Qin J. Pre- and Posttreatment Chest CT Findings: 2019 Novel Coronavirus (2019-nCoV) Pneumonia. 2020:200323.
29. Xie X. Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. *Radiology*. 2020:200343.
30. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020.
31. Chen L, Liu W, Zhang Q. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. 2020;9(1):313-9.
32. Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. *The Journal of infectious diseases*. 2020.
33. Zheng X, Tong Q, Li W, Wang B, Sutter K, Trilling M, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. *Journal of medical virology*. 2020.
34. Lin X. Novel Coronavirus Pneumonia Outbreak in 2019: Computed Tomographic Findings in Two Cases. *Journal of Korean medical science*. 2020;21(3):365-8.
35. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. *Jama*. 2020.
36. Kim JY, Ko JH. Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea. 2020;35(7):e86.
37. Liu C, Jiang ZC, Shao CX, Zhang HG, Yue HM, Chen ZH, et al. [Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a

- multicenter study]. *Zhonghua gan zang bing za zhi* = *Zhonghua ganzangbing zazhi* = Chinese journal of hepatology. 2020;28(2):148-52.
38. Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. *European journal of nuclear medicine and molecular imaging*. 2020.
39. Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. *Emerging microbes & infections*. 2020;9(1):469-73.
40. Pan F, Ye T. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. 2020:200370.
41. Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. *Zhonghua jie he he hu xi za zhi* = *Zhonghua jiehe he huxi zazhi* = Chinese journal of tuberculosis and respiratory diseases. 2020;43(0):E005.
42. Ai T, Yang Z. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. 2020:200642.
43. Liu YC, Liao CH, Chang CF, Chou CC, Lin YR. A Locally Transmitted Case of SARS-CoV-2 Infection in Taiwan. 2020.
44. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *The New England journal of medicine*. 2020.
45. Feng K, Yun YX, Wang XF, Yang GD, Zheng YJ, Lin CM, et al. [Analysis of CT features of 15 Children with 2019 novel coronavirus infection]. *Zhonghua er ke za zhi* = Chinese journal of pediatrics. 2020;58(0):E007.
46. Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. *Journal of medical virology*. 2020.
47. Fang X, Zhao M, Li S, Yang L, Wu B. Changes of CT Findings in a 2019 Novel Coronavirus (2019-nCoV) pneumonia patient. *QJM : monthly journal of the Association of Physicians*. 2020.
48. Gou SM, Yin T, Xiong JX, Peng T, Li Y, Wu HS. [Treatment of pancreatic diseases and prevention of infection during outbreak of 2019 coronavirus disease]. *Zhonghua wai ke za zhi* [Chinese journal of surgery]. 2020;58(0):E006.
49. Li YY, Wang WN, Lei Y, Zhang B, Yang J, Hu JW, et al. [Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with 2019 novel coronavirus pneumonia]. *Zhonghua jie he he hu xi za zhi* = *Zhonghua jiehe he huxi zazhi* = Chinese journal of tuberculosis and respiratory diseases. 2020;43(0):E023.
50. Wang J, Liu J, Wang Y, Liu W, Chen X, Sun C, et al. [Dynamic changes of chest CT imaging in patients with corona virus disease-19 (COVID-19)]. *Zhejiang da xue xue bao Yi xue ban* = *Journal of Zhejiang University Medical sciences*. 2020;49(1):0.
51. Wu J, Wu X, Zeng W, Guo D, Fang Z, Chen L, et al. Chest CT Findings in Patients with Corona Virus Disease 2019 and its Relationship with Clinical Features. *Investigative radiology*. 2020.
52. Tong ZD, Tang A, Li KF, Li P, Wang HL, Yi JP, et al. Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. *Emerging infectious diseases*. 2020;26(5).
53. Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Chest Radiographic and CT Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients Treated in Korea. *Korean journal of radiology*. 2020.

- 375 54. Wei J. 2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed Tomography
376 Findings. *Infection & chemotherapy*. 2020.
- 377 55. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of
378 patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan,
379 China: retrospective case series. 2020;368:m606.
- 380 56. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The
381 epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases
382 (COVID-19) in China]. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue*
383 *zazhi*. 2020;41(2):145-51.
- 384 57. Kam KQ, Yung CF, Cui L, Lin Tzer Pin R, Mak TM, Maiwald M, et al. A Well Infant with
385 Coronavirus Disease 2019 (COVID-19) with High Viral Load. *Clinical infectious*
386 *diseases : an official publication of the Infectious Diseases Society of America*. 2020.
- 387 58. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical Characteristics of Imported
388 Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. *Clinical*
389 *infectious diseases : an official publication of the Infectious Diseases Society of America*.
390 2020.
- 391 59. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-
392 19 associated with acute respiratory distress syndrome. *The Lancet Respiratory*
393 *medicine*. 2020.
- 394 60. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2
395 infection: a nationwide analysis in China. *The Lancet Oncology*. 2020.
- 396 61. Van Cuong L, Giang HTN, Linh LK, Shah J, Van Sy L, Hung TH, et al. The first
397 Vietnamese case of COVID-19 acquired from China. *The Lancet Infectious diseases*.
398 2020.
- 399 62. Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. Asymptomatic cases in a family cluster
400 with SARS-CoV-2 infection. *The Lancet Infectious diseases*. 2020.
- 401 63. Bernheim A, Mei X. Chest CT Findings in Coronavirus Disease-19 (COVID-19):
402 Relationship to Duration of Infection. 2020:200463.
- 403 64. Shrestha R, Shrestha S, Khanal P, Bhuvan KC. Nepal's First Case of COVID-19 and
404 public health response. *Journal of medical virology*. 2020.
- 405 65. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival
406 secretions of patients with SARS-CoV-2 infection. 2020.
- 407 66. Qin C, Liu F, Yen TC, Lan X. (18)F-FDG PET/CT findings of COVID-19: a series of four
408 highly suspected cases. *Journal of medical virology*. 2020.
- 409 67. Kwok KO, Wong V, Wei VWI, Wong SYS, Tang JW. Novel coronavirus (2019-nCoV)
410 cases in Hong Kong and implications for further spread. *The Journal of infection*. 2020.
- 411 68. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and
412 imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-
413 center study in Wenzhou city, Zhejiang, China. *The Journal of infection*. 2020.
- 414 69. Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ, et al. Clinical and computed
415 tomographic imaging features of Novel Coronavirus Pneumonia caused by SARS-CoV-2.
416 *The Journal of infection*. 2020.
- 417 70. Huang WH, Teng LC, Yeh TK, Chen YJ, Lo WJ, Wu MJ, et al. 2019 novel coronavirus
418 disease (COVID-19) in Taiwan: Reports of two cases from Wuhan, China. *Journal of*
419 *microbiology, immunology, and infection = Wei mian yu gan ran za zhi*. 2020.
- 420 71. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
421 Coronavirus Disease 2019 in China. *The New England journal of medicine*. 2020.
- 422 72. Arcavi L, Benowitz NL. Cigarette smoking and infection. *Archives of internal medicine*.
423 2004;164(20):2206-16.
- 424 73. Lawrence H, Hunter A, Murray R, Lim WS, McKeever T. Cigarette smoking and the
425 occurrence of influenza - Systematic review. *The Journal of infection*. 2019;79(5):401-6.

74. Klein SL, Flanagan KL. Sex differences in immune responses. *Nature reviews Immunology*. 2016;16(10):626-38.
75. Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Moller M. The X chromosome and sex-specific effects in infectious disease susceptibility. *Human genomics*. 2019;13(1):2.
76. Robinson DP, Hall OJ, Nilles TL, Bream JH, Klein SL. 17beta-estradiol protects females against influenza by recruiting neutrophils and increasing virus-specific CD8 T cell responses in the lungs. *Journal of virology*. 2014;88(9):4711-20.
77. Rettew JA, Huet-Hudson YM, Marriott I. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. *Biology of reproduction*. 2008;78(3):432-7.
78. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. *The Journal of clinical endocrinology and metabolism*. 2004;89(7):3313-8.
79. Cai G. Tobacco-use disparity in gene expression of ACE2, the receptor of 2019-nCov. *Preprints*. 2020:2020020051.
80. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. *Lancet (London, England)*. 2015;386(9997):995-1007.
81. Quilty BJ, Clifford S, Flasche S, Eggo RM. Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV). *Euro surveillance : bulletin European sur les maladies transmissibles = European communicable disease bulletin*. 2020;25(5).
82. Bwire GM, Paulo LS. Coronavirus disease-2019: is fever an adequate screening for the returning travelers? *Tropical medicine and health*. 2020;48:14.
83. Victoria State Government. 2019 Coronavirus disease (COVID-19) 2020. Available from: <https://www2.health.vic.gov.au/about/news-and-events/healthalerts/2019-Coronavirus-disease--COVID-19>.
84. Government of New York City. COVID-19: Symptoms, Chronic Health Risks 2020. Available from: <https://www1.nyc.gov/site/doh/covid/covid-19-symptoms-chronic-health-risks.page>.
85. King County Government. Public Health: What to do if you have confirmed or suspected COVID-19 or are worried that you may have COVID-19 2020. Available from: <https://www.kingcounty.gov/depts/health/news/2020/March/5-suspected-covid.aspx>.
86. Washington State Department of Health. What to do if you have confirmed or suspected coronavirus disease (COVID-19) 2020. Available from: <https://www.doh.wa.gov/Portals/1/Documents/1600/coronavirus/COVIDcasepositive.pdf>.
87. Ministry of Foreign Affairs and Trade (New Zealand). COVID-19 (Coronavirus) 2020. Available from: <https://safetravel.govt.nz/covid-19-coronavirus>.
88. Government of Telangana Department of Health and Family Welfare (India). Corona Virus 2020. Available from: <http://124.124.103.93/COVID/home.htm>.
89. Saudi Center for Disease Prevention and Control, Ministry of Health (Saudi Arabia). Coronavirus Disease 19 (COVID-19) Guidelines 2020. Available from: <https://www.moh.gov.sa/CCC/healthp/regulations/Documents/Coronavirus%20Disease%202019%20Guidelines%20v1.1..pdf>.
90. Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management. *AJR American journal of roentgenology*. 2020:1-7.
91. Wang K, Kang S, Tian R, Zhang X, Zhang X, Wang Y. Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area. *Clinical radiology*. 2020.

92. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020.
93. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa.
94. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Frontiers of medicine*. 2020.
95. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.
96. Kim JY. Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea. *Journal of Korean medical science*. 2020;35(7):e86.
97. Phan T. Genetic diversity and evolution of SARS-CoV-2. *Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases*. 2020;81:104260.

492 Table 1: Characteristics of COVID-19 patients

Characteristics	Number of patients analyzed	Number/Mean
Age (years)	1,725	49.16
Sex	44,760	
Male		23,032 (51.46%)
Female		21,728 (48.54%)
Smoking status	2,030	
Smokers		968 (47.68%)
Non-smokers		1,062 (52.32%)
Comorbidities	21,020	
Yes		5,451 (25.93%)
No		15,569 (74.07%)
Type of comorbidities	5,450	
Hypertension		2,683 (50.82%)
Diabetes		1,103 (20.89%)
Cardiovascular and cerebrovascular diseases		873 (16.54%)
Respiratory system disease		512 (9.70%)
Malignancy		108 (2.05%)
Presence of symptoms	3,117	
Yes		3092 (99.20%)
No		25 (0.80%)
Signs and symptoms		
Fever	3,097	2577 (83.21%)
Cough	3,097	1912 (61.74%)
Myalgia or fatigue	3,117	942 (30.22%)
Sputum production	3,115	630 (20.22%)
Dyspnea	3,093	525 (16.97%)
Length from illness onset to dyspnea (days)	179	4.99
Headache	3,114	325 (10.44%)
Sore throat	3,117	250 (8.02%)
Chill	3,117	201 (6.45%)
Nausea and vomiting	3,116	142 (4.56%)
Diarrhea	3,113	136 (4.37%)
Chest tightness but not pain	3,117	94 (3.02%)
Nasal congestion or runny nose	3,117	64 (2.05%)
Loss of appetite	3,116	62 (1.99%)
Abdominal pain	3,116	38 (1.22%)
Rhinorrhoea	3,117	35 (1.12%)
Pharyngalgia	3,117	33 (1.06%)
Dizziness	3,117	32 (1.03%)
Chest pain	3,117	25 (0.80%)
Hemoptysis	3,115	23 (0.74%)
Respiratory rate >24 breaths per min	3,117	22 (0.71%)
Malaise	3,117	21 (0.67%)
Heart palpitation	3,117	14 (0.45%)
Conjunctivitis	3,117	10 (0.32%)
Confusion	3,117	10 (0.32%)
Blood in sputum	3,117	3 (0.10%)
Anthralgia	3,117	2 (0.06%)

Gastrointestinal reaction	3,117	1 (0.03%)
Back pain	3,117	1 (0.03%)
Constipation	3,117	1 (0.03%)
Skin tingling	3,117	1 (0.03%)
Somnolence	3,117	1 (0.03%)
Sneezing	3,117	1 (0.03%)
Jaundice	3,117	1 (0.03%)
Respiratory symptoms*	3,117	7 (0.22%)
Laboratory findings		
Leukocyte count ($\times 10^9$ per L)	801	5.60
Decreased	961	232 (24.14%)
Normal	961	606 (63.06%)
Increased	961	123 (12.80%)
Neutrophil count ($\times 10^9$ per L)	571	3.63
Lymphocyte count ($\times 10^9$ per L)	849	0.97
Decreased	827	425 (51.39%)
Normal	827	402 (48.61%)
Hemoglobin, g/L	336	127.47
Platelet count, (10^9 per L)	635	181.58
Decreased	561	54 (9.63%)
Prothrombin time (s)	562	11.94
Activated partial thromboplastin time (s)	360	29.96
D-dimer (mg/L)	726	1.13
D-dimer (mg/L) when one study was removed [†]	645	0.45
Albumin (g/L)	473	36.84
Alanine aminotransferase (U/L)	634	31.55
Aspartate aminotransferase (U/L)	614	32.59
Normal	499	362 (72.55%)
Increased	499	137 (27.45%)
Total bilirubin (mmol/L)	659	12.04
Potassium (mmol/L)	44	4.23
Sodium (mmol/L)	44	138.48
Creatinine (μ mol/L)	633	72.45
Normal	231	219 (94.81%)
Increased	231	12 (5.19%)
Creatine kinase (U/L)	636	93.66
Normal	400	347 (86.75%)
Increased	400	53 (13.25%)
Lactate dehydrogenase (U/L)	547	261.44
Normal	413	224 (54.24%)
Increased	413	189 (45.76%)
Hypersensitive troponin I (pg/mL)	179	5.91
>28 (99th percentile)	28	1 (3.57%)
Procalcitonin (ng/mL)	334	0.21
Normal	359	111 (30.92%)
Increased	359	248 (69.08%)
Increased C-reactive protein	870	629 (72.30%)
CT findings		
Lung involvement	1,144	
Bilateral		898 (78.50%)
Unilateral		179 (15.65%)

No abnormalities		67 (5.86%)
Number of lobes affected	323	
1		55 (17.03%)
2		37 (11.46%)
3		41 (12.69%)
4		57 (17.65%)
5		133 (41.18%)
Complications	342	
Acute respiratory distress syndrome		97 (28.36%)
Acute cardiac injury		27 (7.89%)
Acute kidney injury		26 (7.60%)
Arrhythmia		23 (6.73%)
Shock		20 (5.85%)
Hyperglycemia		18 (5.26%)
Hepatic insufficiency / liver dysfunction		17 (4.97%)
Acute respiratory injury		8 (2.34%)
Hospital acquired/Ventilator associated pneumonia		8 (2.34%)
RNAemia		6 (1.75%)
Secondary infection		4 (1.17%)
Renal insufficiency		2 (0.58%)
Gastrointestinal hemorrhage		2 (0.58%)
Cardiac failure		1 (0.29%)
Pneumothorax		1 (0.29%)
Urinary tract infection		1 (0.29%)
Bacteremia		1 (0.29%)

* Respiratory symptoms included multiple symptoms such as cough and sore throat, but they were not reported separately in the original publications

† Data from Shi et al. (4) was removed as the value reported was an outlier

Figure 1: Flow chart of study selection